A Phase III Trial Comparing Dexamethasone, Aprepitant With or Without Mirtazapine in Delayed Emesis Control and Appetite Improvement

NCT02336750 Phase 3 COMPLETED

Comparing Dexamethasone, Aprepitant and Mirtazapine With Dexamethasone and Aprepitant in Delayed Emesis Control and Appetite Improvement

Details

Lead sponsor	Fudan University
Phase	Phase 3
Status	COMPLETED
Enrolment	212
Start date	2014-12
Completion	2021-12

Conditions

• Breast Cancer

Interventions

• Aprepitant
• Mirtazapine

Primary outcomes

• Delayed emesis control (no vomiting and no rescue treatment during 25-120 hours after initiation of chemotherapy) — 6 days

Countries

China